ArticleOncology letters2018
Establishment and characterization of a GES-1 human gastric epithelial cell line stably expressing miR-23a.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- QSAR Modeling for Predicting ICInternational journal of molecular sciences · 2025Article
- Inhibition of microRNA-155 regulates gastric mucosal barrier repair and inflammation by targeting SOCS1 for the treatment of acute gastritis.Scientific reports · 2025Article
- Tormentic acid, a triterpenoid isolated from the fruits ofPharmaceutical biology · 2023Article
- Repurposing Benztropine, Natamycin, and Nitazoxanide Using Drug Combination and Characterization of Gastric Cancer Cell Lines.Biomedicines · 2023Article
- ANP32E contributes to gastric cancer progression via NUF2 upregulation.Molecular medicine reports · 2022Article
- Extracellular vesicles from gastric epithelial GES-1 cells infected withFrontiers in oncology · 2022Article
- Ochratoxin A-induced genotoxic and epigenetic mechanisms lead to Alzheimer disease: its modulation with strategies.Environmental science and pollution research international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs/miRs) are highly conserved, endogenous, small and single-stranded RNA molecules that promote the degradation and translational inhibition of specific target mRNAs in order to regulate cell proliferation and differentiation, and organism growth and development. MiR-23a has been demonstrated to function as an oncogene in certain types of tumor. The aim of the present study was to provide a tool for elucidating the mechanisms of action of miR-23a in gastric cancer, and identify the function of miR-23a in a human gastric epithelium cell line, by establishing a human gastric epithelial GES-1 cell line that stably expressed miR-23a. A plasmid was constructed for the expression of miR-23a by inserting the miR-23a primary sequence into a pcDNA3 vector (pcDNA3/pri-23a). PcDNA3/pri-23a or the empty pcDNA3 vector (EV), which was then transfected into human gastric epithelium GES-1 cells using Lipofectamine to produce GES-1/miR-23a cells and GES-1/EV cells, respectively. G418 (Geneticin) was used to select and expand the G418-resistant colonies, and miR-23a expression was assessed by reverse transcription-semi-quantitative polymerase chain reaction. The proliferation of the cells was assessed using cell counting and MTT assays. The invasive ability of the cells was evaluated using a Transwell assay. The colony-forming ability of the cells was assessed using a colony formation assay. A human gastric epithelium GES-1/miR-23a cell line with the stable expression of miR-23a was successfully established. Compared with the control GES-1 and GES-1/EV cells, the mRNA expression of the miR-23a gene in GES-1/miR-23a cells was significantly increased (P<0.05). The proliferation rate, invasive ability and colony-forming ability of the GES-1/miR-23a cells were significantly higher compared with those of the control GES-1/EV cells and the parental GES-1 cells (P<0.05). Additionally, the results of the present study demonstrated that miR-23a enhanced the cell proliferation rate, invasive ability and cell colony forming ability of GES-1 cells. This data provides a solid experimental foundation for further studies on the function of miRNAs in the development and progression of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.